Funded by the Wellcome Translational Partnership Award (TPA), and by the 2022-25 MRC UKRI Impact Accelerator Award (IAA) we run an annual Translation Manchester Accelerator Awards call offering two translational funding schemes

We are pleased to announce that our 2022 funding call – Translation Manchester Accelerator Awards (TMAA) – is now open.

This new call brings together two institutional translational research funding streams under one umbrella, with funding available from either MRC (via the 2022-25 UKRI MRC IAA award) or Wellcome (through the Translational Partnership Award, TPA). This represents a unique opportunity for researchers to progress their translational research.

The overall aim of the call is to facilitate progression of research projects along the translational pathway, unlocking bottlenecks, and bringing the University’s innovations closer to patient impact. The TMAA call consists of two funding schemes:

 

Access to Expertise (A2E)

Awards up to the value of £25k, for projects of 6-9 months in duration. Supports access to appropriate technical expertise required by a research group to unlock translational bottlenecks, for example bioinformaticians, statisticians, research nurses and/or clinicians time, regulatory advisors, entrepreneurs in residence or industrial secondments. A2E awards will be funded through the Wellcome TPA. This scheme has a one-stage application process with a deadline on 22 July 2022.

Application brief and application form for the A2E scheme can be downloaded below:

 

 

Confidence for Translation (C4T)

Awards up to the value of £75k, for projects of 6-9 months in duration (exceptionally 12. The award encourages interdisciplinary working to address major challenges in translational research, and support the progression of existing research projects along the translational pipeline. This new scheme combines the former Confidence in Concept (CIC) and Project for Translation (P4T) Schemes from MRC and Wellcome respectively. Successful C4T awards will be funded from either the URKI MRC IAA or the Wellcome TPA with the decision being made by the peer review panel. The C4T call features a 2-stage application process with an initial expression of interest (EoI) deadline of 20 May 2022. Selected applications will be invited to submit a full application with deadline on the 22 July 2022.

Application brief and application form for the C4Tscheme can be downloaded below:

 

 

For all schemes, outcomes will be announced late October 2022 and funding released in late November 2022. 

You can download and read the frequently asked questions for both schemes below:

 

 

Applications for both schemes will be accepted from 25th April 2022, for more information on our activities and future funding opportunities subscribe to our newsletter. For any other queries please contact translation@manchester.ac.uk.

On April 27th we hosted an online information session on the new TMAA call covering the new call structure, the remit of the new schemes, the application process and relevant deadlines. You can watch the event on demand and download the slides from the links below 

 

Previous awards

In previous years Translation Manchester run two translational funding schemes: Access to Expertise (A2E) and Projects for Translation (P4T). 

The overall aim of the schemes is to build better links between science, technology and innovation by removing barriers between disciplines and making it easier for researchers to take the first translational steps and successfully progress along the translational pathway.

Similarly, the Faculty of Biology Medicine and Health has been recipient of the Confidence in Concept award from MRC for several years supporting projects with similar remit.

Details of previous awards from both TPA and MRC can be found below:

Projects for Translation (P4T)

2021 Awards

Richard Edmonson
Investigating the DNA damage response in ovarian cancer
9 months of P4T support

Stuart Ellison
At scale transduction of hCD34+ stem cells for Wolman disease biodistribution studies
9 months of P4T support

Lydia Tabernero
Developing novel medicines to tackle difficult-to treat mycobacterial infections
9 months of P4T support

Kathryn Else
Refining imidazopyridines: new anthelmintics targeting whipworm
9 months of P4T support

2020 awards

Alan McWilliam
Remote cardiac monitoring in patients follow lung cancer radiotherapy
9 months P4T support

Claudia Lindner
An Automated Software System for Monitoring Developmental Dysplasia of the Hip in Children
9 months P4T support

Jeremy Derrick
Using novel virus-like particle engineering to generate a second generation COVID-19 vaccine
9 months P4T support

Josef Schlittenlacher
Hearing Health: Personalised hearing-aid fitting using suprathreshold tests
12 months P4T support

Rachel Watson
Systemic sclerosis-related calcinosis: developing safe, effective topical treatments to reduce pain, ulceration and disability (TOPiCAL) project
6 months P4T support

2018 awards

Brian Bigger
Establish manufacturing scale-up of lentiviral transduction of peripheral blood derived CD34+ stem cells at GMP
9 months P4T support

Tony Day & Caroline Milner
Development of Link_TSG6 as a protein biological with disease-modifying and anti-inflammatory properties
9 months P4T support

Mike Bromley
Project title: A point of Care Diagnostic for Fungal Keratitis
6 months P4T support

Ellen Poliakoff
Action Imagery and Observation in Neurorehabilitation for Parkinson’s Disease (ACTION-PD)
6 months P4T support

William Newman
Development and implementation of a point-of-care pharmacogenetic test to avoid antibiotic-related hearing loss in neonates
12 months P4T support

Access to Expertise (A2E)

2021 Awards

Martin Fergie
Development of a commercialization strategy for hypothesized interaction distribution as a patient stratification biomarker in follicular lymphoma
6 months of consultancy for commercialisation, regulatory and Intellectual Property advice

Pauline Whelan
Securing medical device regulatory expertise for a digital health platform to support people with Cystic Fibrosis
6 months of consultancy for medical device regulatory advice

Samuel Jones
Identifying the commercialization pathway for broad- spectrum antiviral polymers
5 months of consultancy to develop commercialisation plan

Sarah Cartmell
Novel Tendon Repair – Gap Analysis in preparation for a first in man trial
3 months of consultancy for MHRA gap analysis and design of clinical trial protocols

Sean Knight
Resolving inflammation and clinical recovery from COVID-19
12 months research nurse time to faciitate sample collection

Silke Brix
Prediction Tools to personalise medicine in ANCA- associated vasculitis
8 months of biostatistical expertise

2020 awards

Adam Reid
ComplexWounds@Manchester – Biobank
12 months access to research nurse

Claudia Lindner
Establishing a data sharing platform between clinicians and researchers for studying children’s hip diseases
8 months access to IT and imaging expertise

James Eales
A non-invasive “liquid biopsy” for chronic kidney disease
6 months access to expertise in single cell sequencing

Matthew Gittins
Improving patient outcomes and experience – translating stroke research expertise to Vestibular Schwannoma
12 month access to biostatics expertise and clinician time

Patrick Hamilton
Antigen specific therapy for Autoimmune Membranous Nephropathy (AMN)
9 months access to technical experimental expertise within a commercial company

Samuel Jones
Identifying the pathway to the clinic for broad spectrum antiviral polymers
6 months access to clinical trial expertise

2019 awards

Silke Brix
Risk stratification and modified immunotherapy to reduce mortality in elderly patients with ANCA-associated glomerulonephritis
4 months access to statistical expertise

Govind Oliver
Technology enhanced care in cardiac arrest
8 months access to software development expertise and clinician time

Paul Bishop
In-silico prediction of potential for immunogenicity of AMD therapeutics
3 months access to in silico evaluation expertise

Anna Woollams
Using clinical imaging to optimise therapy for individuals with aphasia
9 months access to app development and delivery expertise

James Fildes
Developing an arterial leukocyte filter that mimics leukocyte adhesion
6 months access to external peptide synthesis expertise

Jordi Bella
Engineered recombinant collagens for tissue regeneration applications
9 months access to expertise in TPP development

Tony Day
Development of Link-TSG6 as a protein biological with disease-modifying and anti-inflammatory properties
5 months access to bioinformatics expertise

Emma Gowen
Developing a partnership between Autism@Manchester and GMMH NHS autism services
9 months access to clinician and research co-ordinator time

2018 awards

Kathryn Abel
mSootheBox: Developing a Digital Health Intervention for Self Harm Management for Children and Young People
9 months access to augmented reality expertise and funds to establish an expert Research User Group

Jordi Bella
Cost of goods model for the manufacture of engineered recombinant collagens for tissue regeneration applications
6 months access to expertise to develop a cost of goods model.

Jeremy Derrick
Stratification by Immuno-profiling of IgG in Rheumatoid Arthritis and Psoriasis Patients
3 months access to informatics expertise 

Tracy Hussell
Macrophage adaptation in the inflamed lung
12 months access to clinician time for clinical sample collection

Matthias Pierce
‘CAPRI’: Children and Adolescents with PaRental mental Illness: Understanding the ‘who’ and the ‘how’ of targeting interventions
9 months access to an expert health economist

Stephen Richardson
Development of an adipose stem cell-GDF6 regenerative therapy for intervertebral disc degeneration and back pain
9 months access to an expert health economist and expert Research User Group

Mark Travis
Determining a novel pathway that controls TGF-beta activation in the human immune system
3 months access to research nurse and clinician time for clinical sample collection

Confidence in Concept (Cic)

Round 7

Prof Perdita Barran, FSE  

Smell-led volatile biomarker discovery from sebum and breath for tuberculosis diagnosis

Prof Brian Bigger, FBMH  

Evaluation of genotoxicity & scale up transduction of HSC Gene Therapy for MPSII

Prof Giulio Cossu, FBMH  

Immortal, universal donor cells for the ex vivo gene therapy of muscular dystrophy: development of a pre-clinical mouse model

Prof Tony Day, FBMH        

Proof of concept for Link_TSG6 as a protein-based biologic for wet Age-Related Macular Degeneration (AMD)

Dr Mark Dunne, FBMH      

Assay Detection for Focal Congenital Hyperinsulinism

Dr Katie Finegan, FBMH   

Exploring the utility of targeting ERK5-signalling to treat idiopathic pulmonary fibrosis (IPF)

Prof Anthony Jones, FBMH          

Neurofeedback platform for long-term use in patients with chronic arthritic pain

Prof Lydia Tabernero, FBMH       

Development of anti-virulence agents for tuberculosis treatment

Prof Catharine West, FBMH        

Translation of a hypoxia gene signature for use in bladder cancer onto a clinically applicable measurement platform

Round 6
Project Title Principal Investigator

Development of a novel treatment for age-related macular degeneration

Professor Paul Bishop 

Development of VRAC inhibitors as new anti-inflammatory agents

Dr David Brough 

CCR2-targeted peptide-drug conjugates for the treatment of CMML

Dr Sam Butterworth 

Validation of a novel immunomodulatory approach to the treatment of Triple Negative Breast Cancer

Dr Katie Finegan 

Development of blood-based proteomic biomarkers of Alzheimer’s disease

Professor Nigel Hooper 

Automated Low Dose Risk Assessment Mammography (ALDRAM): defining breast cancer risk to reach the unreached

Dr Sacha Howell 

Computer-Aided Surgical Planning (CASP): Feasibility of the First Surgical Planning Platform for Coronary Artery Bypass Grafting 

Dr Amir Keshmiri 

Validation of secreted markers and Biochip Assay development for use in clinical and commercial scaleup of pluripotent stem cells

Professor Susan Kimber 

Screening for Biomarkers in Synovial Fluid to Stratify Osteoarthritis Patients

Professor Qing-Jun Meng 

Dynamic glucose-enhanced (DGE)-MRI for non-invasive detection of altered blood-brain barrier glucose transport in dementia

Dr Laura Parkes 

Can clinical imaging be used to predict the optimal type of therapy for aphasia?

Dr Anna Woollams 
Round 5
Project Title Principal Investigator
Investigation of Strathclyde minor groove binders as antifungal agents Dr Michael Bromley (FBMH)

Optimisation of a novel chimeric protein to promote its cell secretion for the treatment
of age-related macular degeneration by gene therapy

Dr Simon J Clark (FBMH)
Development of ‘QuickWord’ Aphasia Software as a novel and promising approach to the treatment of Anomia after Stroke Dr Paul Conroy (FBMH)
Do plasma proteomic patterns relate to CNS changes and predict syndromes and course of schizophrenia? Towards improved diagnosis and prognosis of schizophrenia Prof Bill Deakin (FBMH)
A Novel Diagnostic Method to Stratify Anti-Drug Antibody Responses in Rheumatoid Arthritis Patients by Immunosignature Profiling Prof Jeremy Derrick (FBMH)
Development of fenamate NLRP3 inflammasome inhibitors as potent treatments for the neuropathological, synaptic and cognitive symptoms of Alzheimer’s disease Dr John Gigg (FBMH)
Feasibility study of photoacoustic imaging for early diagnosis and risk stratification of severe digital ischaemia in systemic sclerosis-spectrum disorders Prof Ariane Herrick (FBMH)
Stimulating the brain to reduce chronic pain in the elderly Professor Anthony Jones(FBMH)
Using Gene Expression Data for the Diagnosis of Childhood Growth Hormone Deficiency Dr Philip Murray (FBMH)
Action Imagery and Observation in Neurorehabilitation for Parkinson’s Disease (ACTION-PD): User-informed development of a personalised home-based therapy Ellen Poliakoff (FBMH)
Self-healing, Biocompatible ‘NanoGlue’ for Repair of Meniscal Tears Dr Stephen Richardson (FBMH)
Round 4
Project Title Principal Investigator
Validation of hematopoietic stem cell gene therapy for Mucopolysaccharidosis IIIB in human CD34+ stem cells Dr Brian Bigger (FMHS)
Imaging of synaptic density in neurodegenerative conditions using PET-MR Dr Herve Boutin (FMHS)
Mast cell activation assay – a robust and novel tool to diagnose clinical food allergy Prof Silvia Bulfone-Paus (FMHS)
Elevated Copper in Human Diabetic Nephropathy: A New Therapeutic Target?

Prof Garth Cooper (FMHS)

Infrared Spectral Pathology on Glass Slides Prof Peter Gardner (FEPS)
Using gallium labelled prostate specific membrane antigen (68GA PSMATHP) to guide patient selection for extended pelvic lymph-node dissection Prof Alan Jackson (FBMH)
Development of a predictive tool for subsequent biologic response and adverse events in rheumatoid arthritis patients treated with TNF-a inhibitors Dr Meghna Jani (FMHS)
Advanced characterisation of tumour hypoxia using PET-MRI to personalise radiotherapy for cervical cancer patient Dr Lucy Kershaw (FMHS)
Kinectin frailty Prof Harm van Marwijk (FMHS)
Advanced nerve guidance conduits for peripheral nerve repair

Dr Adam J Reid (FMHS)

Bringing quantitative nailfold capillaroscopy into the clinic Prof Chris Taylor (FMHS)
Novel dual chemokine receptor inhibitors targeting endometrial cancer spread Prof Kaye Williams (FMHS)
Round 3
Project Title Principal Investigator
Anti-PLA2R immunoadsorption therapy for membranous nephropathy patients Prof Paul Brenchley (FMHS)
A novel therapeutic for OA: generation of new IP Prof Tony Day (FLS)
Adaptation of a virus-like particle platform for high throughput vaccine antigen selection Prof Jeremy Derrick (FLS)
Cognitive biomarkers for drug development: evidence for psychopharmacological modulation of a novel test battery

Prof Rebecca Elliott (FMHS)

Increasing donor heart availability for transplantation using ex-vivo perfusion Dr James Fildes (FMHS)
In vivo characterization of the inflammatory component of carotid plaques using PET/ CT and PET/MR in order to develop non-invasive prognostic imaging markers for stroke Dr Alex Gerhard and Dr Sarah Skeoch (FMHS)
The use of a semi-autologous structural bone graft to improve the clinical outcome of revision hip arthroplasty Prof Judith Hoyland (FMHS)
Inhibition of epidermal Langerhans cell (LC) migration with soft drugs (SD) as a novel therapeutic strategy for the treatment of psoriasis Prof Ian Kimber (FLS) and Prof Chris Griffiths (FMHS)
Repositioning of urea cycle disorder drug for inherited retinal disease Dr Forbes Manson (FMHS)
Pilot investigation of polarisation sensitive optical coherence tomography as a non-invasive measure of skin fibrosis Dr Andrea Murray (FMHS)
MRI-based Diffusion Orientation Complexity (DOC) A Non-Invasive Novel Biomarker of cardiac fibrosis and heart failure Dr Josephine Naish (FMHS)
A novel regenerative therapy for IVD degeneration and treatment of low back pain Dr Stephen Richardson (FMHS)
Enriching biomarker identification – earlier diagnosis of Prostate Cancer Prof Paul Townsend (FMHS)
Automated prognostic cellular pattern recognition in pathology using multicoloured Luminsphere biolabels & multispectral microscopy Prof Michael Turner (FEPS)
Round 2
Project Title Principal Investigator
Developing cell/gene therapies for heritable fibrillinopathies Prof Cay Kielty (FLS)
Towards a mobile health device for day-to-day monitoring of Parkinson’s disease Prof Sonja Kotz (FMHS)
To develop a novel treatment for hypertrophic cardiomyopathy Prof Christopher Miller (FMHS)
New target identification for neurodevelopmental disorders through development of a neuro immune animal model

Prof Jo Neill (FMHS)

Development of novel topical therapies for Raynaud’s phenomenon Prof Ariane Herrick (FMHS)
Gene therapy to restore vision in retinal dystrophies Prof Rob Lucas (FLS)
Improved drug discovery in psychiatry using arterial spin labeling based quantitative pharmacological magnetic resonance imaging Dr Shane McKie (FMHS)
Accelerating the early phase development of a new therapeutic for the treatment of small cell Lung cancer (SCLC) Dr Harmesh Aojula (FMHS)
Chimeric Antigen Receptor (CAR) T-Cell Therapy for Ovarian Cancer Dr David Gilham (FMHS)
Development of a validated clinical and research tool for measuring musculoskeletal disease severity using passive motion and position sensing Dr Will Dixon (FMHS)
Dysphagia in early stage Huntington’s disease: A multimodal imaging approach to target stimulation based therapies Prof Shaheen Hamdy (FMHS)
Identification of novel REV-ERB agonists with anti-inflammatory action Prof David Ray (FMHS) and Prof Andrew Loudon (FLS)
Development of novel inflammasome inhibitors for the treatment of Alzheimer’s disease Dr David Brough (FLS)
A new treatment for tuberculosis by targeting MptpB phosphatase Dr Lydia Tabernero (FLS)
Development of a novel therapy to treat fungal infection Prof Mike Bromley (FMHS)
Repositioning of an anti-epileptic drug for anti-arrhythmic treatment Prof Xin Wang (FLS)
Round 1
Project Title Principal Investigator
Optimisation of an anti-angiogenic opticin peptide for eye diseases Prof Paul Bishop (FMHS)
Development of a novel therapeutic approach to cardiac hypertrophy and heart failure Dr Elizabeth Cartwright (FMHS)
Development of point-of-care microbial safety monitors for peritoneal and haemodialysis patients Dr Curtis Dobson (FLS) 
Chondrocytes from human embryonic stem cells for the clinical repair of cartilage defects Prof Sue Kimber (FLS)
Resorbable magnesium alloys for bone repair applications Dr Julie Gough (FEPS)
Exploitation of Genome wide association markers for cognitive decline Dr Neil Pendleton (FMHS) and Prof. John Quinn (University of Liverpool)
Arterial Spin Labelled MRI – an imaging biomarker of cerebral blood flow in children Dr Laura Parkes (FMHS) and Prof. Graham Kemp (Liverpool)
Molecular subtyping of diffuse large B-cell lymphoma (DLBCL) – developing a simple and inexpensive method for routine clinical use Dr Kim Linton (FMHS) and Prof. Andrew Pettit (Liverpool)
Graphene as a vehicle for drug delivery Prof Robert Dryfe (FEPS)
Role of Graphene combined with electrical stimulation in the acceleration of wound repair Dr Ardy Bayat (FMHS)
Graphene-based MRI contrast agents Prof Steve Williams (FMHS)
Edge-specific reactions of biomolecules with graphene flakes on surfaces Dr Chris Blanford (FEPS)
Nanocomposite Graphene Biomaterials and Bionanofilm Platform Prof Jian Lu (FEPS)
Assessing graphene oxide as a matrix for DNA repair and DNA damage assays Prof Geoff Margison (FMHS)
Antimicrobial properties of graphene oxide Prof Ian Roberts (FLS)